Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.
about
High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomasThe intracellular domain of ErbB4 induces differentiation of mammary epithelial cellsCharacterisation of HER heterodimers in breast cancer using in situ proximity ligation assayDifferential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells.Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis.Host nucleotide polymorphism in hepatitis B virus-associated hepatocellular carcinomaContribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma TreatmentsLipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma.Multiplex photoacoustic molecular imaging using targeted silica-coated gold nanorodsTDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation.Multiple cytoskeletal pathways and PI3K signaling mediate CDC-42-induced neuronal protrusion in C. elegans.Targeting the dimerization of epidermal growth factor receptors with small-molecule inhibitors.Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinomaDetection of elevated plasma levels of epidermal growth factor receptor before breast cancer diagnosis among hormone therapy users.Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapyType I gamma phosphatidylinositol phosphate kinase modulates invasion and proliferation and its expression correlates with poor prognosis in breast cancer.Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation.HER4 D-box sequences regulate mitotic progression and degradation of the nuclear HER4 cleavage product s80HER4.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Discovery and validation of breast cancer early detection biomarkers in preclinical samplesExpression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer.Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.MUC4 overexpression augments cell migration and metastasis through EGFR family proteins in triple negative breast cancer cells.The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer.HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression.Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cellsMetaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epitheliumErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays.Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancerThe prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : HER1-4 protein expression and prognosis in pancreatic cancer.Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.
P2860
Q21195240-CFE6353E-FDBE-4857-95E0-57459A1EDD72Q24296970-F1BFBDE7-7CB7-451D-B3F2-ADB3C75C7E86Q24337937-2DA36AC3-220A-416E-850F-A122E9021F2DQ24813382-FA39181E-A3EE-4DA5-A65D-5A2CC3B222A7Q25257542-4A5E8FA2-7BF1-4899-8E1B-B6AD00B7E511Q26750792-EA039A5D-ED29-4137-9B41-CDDB4F6B82EAQ28547357-A772432B-4B20-4F52-AFDF-B27AA9E1D958Q30366990-87017D96-D598-4ADE-8E47-555FB8DCDBA7Q30430971-47F94A08-0ED9-4A17-9EE3-EDBC4DBB3746Q30474840-2D7A2610-DCFD-4529-9600-DA3F9B4A26C7Q33348778-4887B02E-4476-459B-A050-A114F41D6D8FQ33573214-747CEBDD-ED0A-4C9E-8335-2D54A9ABB117Q33574021-C7144E34-8B62-4DE3-8F38-75D4BC4BF9D4Q33593895-21440522-187C-4CBC-9F2D-30B62CF5E8EBQ33722935-254F8867-78BE-42B9-BF94-1A163CDDB3FAQ33873330-7A4DC6D0-2044-48FB-847B-C0F4AE455AADQ33892896-C790A2BF-0D71-4A00-BF12-16CFD464C5CCQ34036131-27656462-913A-4CFA-990D-9467EA077D08Q34048293-39585865-45CD-4EE2-B33B-132656A53834Q34103963-72614EEC-3CA5-4796-9D7F-D1A205095F87Q34200678-756B3779-860E-4767-9607-1D64F4DFAB13Q34428742-EEC1415F-48FE-4C9D-819D-54FDAD0963BAQ34496697-2183B570-B1BB-4357-877D-BC98AE0E9AA1Q34577467-2A3E666D-2F08-4C1C-808F-E5735F3B3885Q34585874-6A10F9F9-7A5D-408E-8F38-291DCA2BAB49Q34982010-474EA171-6D95-49FA-834C-98AA6DE9AA08Q35012797-A182F51E-E346-42D7-9895-951B42045FBFQ35071151-453979EA-8068-4565-8C1E-1F1CD7CC7AC7Q35094456-9957D35D-5D4D-491A-9C0D-B31EA91AB081Q35157568-71068F3E-CD5B-4795-9C92-79ECDE58943EQ35221906-8630113C-4151-4006-B4F5-4836F8F07567Q35379924-F470BCF0-38A2-4293-8AD0-8A41355323B2Q35588724-FC33A211-8060-45D7-860F-D904FB6A9E13Q35657873-6F2069E1-2A8D-4560-9FCE-CF51B453B9D8Q35755192-01215740-B876-41D2-845B-893B3A7E9804Q35889941-F38456E5-C4FE-4328-A898-8BBE86F1DA3CQ36026180-1081499D-19A9-4937-A5C8-D3BE3346348BQ36092726-AE54D0CC-EEF4-4CFA-89C7-D4675A24410CQ36200253-F05FEA35-6CCD-4E39-B7DF-7C2D3225D65FQ36288449-9C3D20D0-9FEB-4557-AE91-7AE52734B509
P2860
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Expression and co-expression o ...... in invasive breast carcinoma.
@ast
Expression and co-expression o ...... in invasive breast carcinoma.
@en
type
label
Expression and co-expression o ...... in invasive breast carcinoma.
@ast
Expression and co-expression o ...... in invasive breast carcinoma.
@en
prefLabel
Expression and co-expression o ...... in invasive breast carcinoma.
@ast
Expression and co-expression o ...... in invasive breast carcinoma.
@en
P2093
P2860
P356
P1476
Expression and co-expression o ...... in invasive breast carcinoma.
@en
P2093
D M Abd El-Rehim
J F R Robertson
R I Nicholson
R S Rampaul
R W Blamey
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602184
P407
P577
2004-10-01T00:00:00Z